Expects cash and cash equivalents will fund the business into 2026. Reports Q1 revenue $190K, consensus $3.33M. “Preparations are underway for the potential approval and commercial launch of govorestat for the treatment of Classic Galactosemia in the US and EU, following the significant regulatory progress we have already made in 2024,” said CEO Shoshana Shendelman. “We are also discussing a potential NDA submission for SORD Deficiency with the Neurology Division at FDA, further advancing our objective of bringing first ever treatment to patients with rare diseases.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics Reports First Quarter 2024 Financial Results
- Applied Therapeutics Welcomes Dale Hooks as New CCO
- Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
- Applied Therapeutics appoints Dale Hooks as CCO
- Applied Therapeutics to present data from study of caficrestat in DbCM